logo-loader
RNS
BioPharma Credit PLC

BioPharma Credit PLC - Result of AGM

RNS Number : 7348I
BioPharma Credit PLC
17 June 2026
 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

 

RESULT OF 2026 ANNUAL GENERAL MEETING

 

The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions put to the meeting were passed by way of a poll.

 

 

Resolutions

Votes

For

%

Votes

Against

%

Total Votes

% of Total Voting Rights Voted

Votes Withheld1

1: To receive the annual report and financial statements

460,319,072

 

100.00

 

9,391

 

0.00

 

460,328,463

 

41.02

 

29,397

 

2: To approve the Directors' Remuneration Report

459,702,819

 

99.93

 

304,467

 

0.07

 

460,007,286

 

40.99

 

350,574

 

3: To elect Nigel Reynolds as a Director

454,734,008

 

98.80

 

5,538,639

 

1.20

 

460,272,647

 

41.02

 

85,213

 

4: To re-elect Harry Hyman as a Director

386,975,634

 

84.08

 

 

73,261,943

 

15.92

 

460,237,577

 

41.01

 

120,283

 

5: To re-elect Stephanie Léouzon as a Director

460,136,435

 

99.98

 

113,279

 

0.02

 

460,249,714

 

41.01

 

108,146

 

6: To re-elect Sapna Shah as a Director

460,150,842

 

99.98

 

 

99,498

 

0.02

 

460,250,340

 

41.01

 

107,520

 

7: To re-elect Rolf Soderstrom as a Director

460,158,519

 

99.98

 

91,821

 

0.02

 

460,250,340

 

41.01

 

107,520

 

8: To re-appoint Ernst & Young LLP as Auditor to the Company

459,861,709

 

99.91

 

421,789

 

0.09

 

460,283,498

 

41.02

 

74,362

 

9: To authorise the Directors to determine the remuneration of the Auditor

460,192,598

 

99.98

 

86,665

 

0.02

 

460,279,263

 

41.02

 

78,597

 

10: To approve the Company's dividend policy

460,324,297

 

100.00

 

7,292

 

0.00

 

460,331,589

 

41.02

 

26,271

 

11: To increase the limit on the aggregate

remuneration payable to the Directors

459,075,861

 

99.77

 

1,078,453

 

0.23

 

460,154,314

 

41.00

 

203,546

 

12: To authorise the allotment of shares by the Company

460,195,439

 

99.98

 

114,466

 

0.02

 

460,309,905

 

41.02

 

47,955

 

13: To authorise the disapplication of pre-emption rights

460,048,383

 

99.96

 

169,868

 

0.04

 

460,218,251

 

41.01

 

139,609

 

14: To authorise the Company to make market purchases

of ordinary shares

456,080,722

 

99.08

 

4,241,966

 

0.92

 

460,322,688

 

41.02

 

35,172

 

15: That a general meeting may be called on not less than 14 clear days' notice

459,691,627

 

99.86

 

632,855

 

0.14

 

460,324,482

 

41.02

 

33,378

 

 

1.     A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.

 

Copies of resolutions 11 to 15 have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

17 June 2026

 

 

Enquiries:

 

BioPharma Credit plc

 

via MUFG Corporate Governance Limited

 

Company Secretary

 

+44 (0) 333 300 1932

 

Burson Buchanan

 

Helen Tarbet / Jamie Hooper / Henry Wilson / Nick Croysdill

 

+44 (0)20 7466 5000

 

biopharmacredit@buchanan.uk.com

 

 

 

Notes to Editors:

 

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

 

 

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSFDFMWEMSELM
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read